|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Xpention Genetics, Inc. Successfully Completes Gene Synthesis and Expression
9/25/2008 9:06:18 AM
CONIFER, CO--(Marketwire - September 25, 2008) - Xpention Genetics, Inc. (OTCBB: XPNG) recently signed a contract with AbD Serotec, a subsidiary of MorphoSys AG, one of the world's leading antibody technology companies, to develop custom recombinant monoclonal antibodies for revalidating and updating the p65 cancer detection test. The first two phases of the contract, p65 gene synthesis and expression, were recently successfully completed. The next phase of the contract has been initiated and is directed at finding high affinity binders to p65. Upon completion, binders with assay potential will be delivered to us for p65 assay revalidation.
|
|
|
|
|
|
|
|
|
|
|